ACE-031
ActRII-Fc Fusion — Decoy Receptor for Myostatin
01
Overview
ACE-031 is a recombinant fusion protein consisting of the extracellular domain of the activin receptor type IIB (ActRIIB) linked to a human IgG1 Fc domain. It functions as a soluble decoy receptor that binds myostatin and related TGF-β ligands, preventing them from engaging their native receptors on muscle tissue.
02
Mechanism of Action
ACE-031 circulates as a soluble fusion protein, capturing myostatin, GDF-11, and activin before they reach ActRII receptors on muscle cell surfaces. This prevents Smad2/3-mediated inhibition of muscle growth, resulting in hypertrophy. The Fc domain extends its circulating half-life to approximately 2 weeks.
03
Research Highlights
Phase I clinical trial in healthy postmenopausal women shows dose-dependent lean mass increase
Duchenne muscular dystrophy Phase II trial demonstrates functional improvement before early termination
Receptor selectivity profiling confirms high-affinity binding to myostatin and GDF-11
04
Dosage
Administration & Timing
Subcutaneous (SC) injection into abdominal or gluteal subcutaneous tissue, typically once weekly. Research protocols in neuromuscular disease trials used weekly dosing.
Dosage Guidelines
Cycle Length
4–12 weeks in published clinical-trial research; development discontinued.
05
Reconstitution
Solvent
Bacteriostatic Water (0.9% benzyl alcohol)
Volume
Per research formulation
Concentration
Per protocol
Storage
Lyophilized powder: store at -20 °C long-term. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Notes
ACE-031 is a recombinant fusion protein (ActRIIB-Fc) that traps myostatin. Clinical development was halted — limited availability.
Research Reference Only
Dosage and reconstitution values reflect commonly cited ranges from published research literature and are presented for educational and research reference only. This is not medical advice or a dosing recommendation. HEXAGEN does not endorse human use of any compound. Always consult a qualified healthcare professional.
Research Disclaimer
ACE-031 is for educational and research purposes only. Not intended as medical advice. Consult a qualified healthcare professional before making any health-related decisions.
Related Compounds
View All
ACE-031 Knowledge Graph
Explore how ACE-031 connects to mechanisms, research goals, related compounds, research stacks, and scientific references. Drag nodes, zoom, and filter by type.
No nodes match the active filters.
ACE-031 — Common Research Questions
What is ACE-031?
ACE-031 is a recombinant fusion protein consisting of the extracellular domain of the activin receptor type IIB (ActRIIB) linked to a human IgG1 Fc domain. It functions as a soluble decoy receptor tha... ACE-031 belongs to the Other research category and is studied for its actrii-fc fusion — decoy receptor for myostatin.
How does ACE-031 work?
ACE-031 circulates as a soluble fusion protein, capturing myostatin, GDF-11, and activin before they reach ActRII receptors on muscle cell surfaces. This prevents Smad2/3-mediated inhibition of muscle growth, resulting in hypertrophy. The Fc domain extends its circulating half-life to approximately 2 weeks.
What are the key research benefits of ACE-031?
Decoy receptor trapping of myostatin and activin. Broad TGF-β ligand neutralization. Significant lean mass gains in clinical research. Duchenne muscular dystrophy research applications. Preserved receptor selectivity via ActRIIB domain. Clinical-grade manufacturing with documented safety data.
What is the molecular structure of ACE-031?
ACE-031 is a research compound in the Other category. Detailed molecular structure data is being compiled. Refer to primary literature for structural analysis.
What does the research say about ACE-031?
Phase I clinical trial in healthy postmenopausal women shows dose-dependent lean mass increase Duchenne muscular dystrophy Phase II trial demonstrates functional improvement before early termination Receptor selectivity profiling confirms high-affinity binding to myostatin and GDF-11 These findings are based on preclinical and clinical research. ACE-031 is a research compound and these studies do not constitute medical advice.
Is ACE-031 FDA approved?
No. ACE-031 is not FDA-approved for any indication. It is a research chemical studied in preclinical and early clinical research. These compounds are not approved for human therapeutic use and should only be studied in appropriate research settings.
What category does ACE-031 belong to?
ACE-031 belongs to the Other category, which focuses on a collection of specialized peptides studied across various physiological domains including reproductive health, pigmentation, and growth factor signaling. You can explore more compounds in this category on the Other pillar page.
Related Articles
PT-141: Central Nervous System Activation of Sexual Desire
Understanding how PT-141 differs from PDE5 inhibitors and its Phase III HSDD clinical trial data.
DSIP: Delta Sleep-Inducing Peptide
The discovery, mechanism, and stress-modulation research behind DSIP's sleep-promoting effects.
Kisspeptin: The Gatekeeper of the HPG Axis
How Kisspeptin's pulsatile signaling controls GnRH release and its implications for reproductive research.
Scientific References
Phase I clinical trial in healthy postmenopausal women shows dose-dependent lean mass increase
Duchenne muscular dystrophy Phase II trial demonstrates functional improvement before early termination
Receptor selectivity profiling confirms high-affinity binding to myostatin and GDF-11